COMMUNIQUÉS West-GlobeNewswire

Sight Sciences to Report Third Quarter Financial Results on November 7, 2024
17/10/2024
MENLO PARK, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, [...]
Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial
17/10/2024
Clinical Complete Responses Observed in 4 out of 5 Patients in Subset of Patients with Low Grade Disease; Evidence of Bladder Urothelial Field Effect in Non-Target Tumors Favorable Safety Profile Observed; Only Grade 1 [...]
TELA Bio to Announce Third Quarter 2024 Financial Results
17/10/2024
MALVERN, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today [...]
23andMe Introduces New Feature Helping African Americans Trace Their Roots to Post Slavery Communities in the South
17/10/2024
The new African American Genetic Groups feature traces customers' ancestral connections from before the early-to-mid-20th century migrations to more than 200 communities in Southern states SUNNYVALE, Calif., Oct. 17, [...]
ClearPoint Neuro to Announce Third Quarter 2024 Results November 7, 2024
17/10/2024
SOLANA BEACH, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine [...]
Seer to Report Third Quarter 2024 Financial Results on November 6, 2024
17/10/2024
REDWOOD CITY, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial [...]
Intuitive Announces Third Quarter Earnings
17/10/2024
SUNNYVALE, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial [...]
Anika Announces Third Quarter 2024 Results Conference Call Date
17/10/2024
BEDFORD, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2024 [...]
Signature d’un avenant n°3 au contrat de financement obligataire en vigueur pour assurer le retournement stratégique de Safe
17/10/2024
Avertissement : La société SAFE SA (la « Société ») a mis en place un financement sous forme d’obligations convertibles en actions nouvelles ou existantes (OCEANE) avec Global Corporate Finance Opportunities 20 (« GCFO [...]
SpyGlass Pharma Presents Promising 18-month Data of its Innovative Drug Delivery Platform Implanted During Routine Cataract Surgery in Eyes with Glaucoma
17/10/2024
Mean intraocular pressure (IOP) was reduced by 43.7% from baseline at month 18 All patients remained off topical IOP-lowering medications and achieved >20% IOP reduction All eyes achieved Visual Acuity (BCDVA) of 20/ [...]
Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV
17/10/2024
Data Show Tesamorelin May Reduce CVD Risk by Reducing EVAF MONTREAL, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company [...]
Les présentations de Theratechnologies lors de l’IDWeek mettent en évidence l’incidence de l’excès de graisse viscérale abdominale sur le risque de maladie cardiovasculaire chez les personnes vivant avec le VIH
17/10/2024
Selon les données, la tésamoréline pourrait réduire le risque de maladie cardiovasculaire en diminuant l’excès de graisse viscérale abdominale MONTRÉAL, 17 oct. 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« [...]
Wyatt Surgery Center Selects Nextech Platform for Revenue Cycle Management
17/10/2024
Billing Services Drives Significant Increase in Collections and Cash Flow TAMPA, Fla., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Nextech, market leader of comprehensive technology solutions for specialty physician practices, [...]
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
17/10/2024
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Paris, 17 October, 2024, 7.30pm CET AB Science SA ( [...]
AB Science fait le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLA
17/10/2024
COMMUNIQUE DE PRESSE AB SCIENCE FAIT LE POINT SUR LA DEMANDE D'AUTORISATION CONDITIONNELLE DE MISE SUR LE MARCHÉ DU MASITINIB DANS LE TRAITEMENT DE LA SCLÉROSE LATÉRALE AMYOTROPHIQUE Paris, 17 octobre 2024, 19h30 AB [...]
Enlitic Acquires Laitek, Revolutionizing Medical Imaging Data Management
17/10/2024
Enlitic raises AU$22.5M to fund acquisition and ongoing operations Highlights Enlitic’s acquisition of LAITEK advances Enlitic’s strategic roadmap and represents an inflection point for the Company Enlitic has raised AU [...]
OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index
17/10/2024
NANTES, France, October 17, 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) , today announced it will be presenting its novel OSE-CYTOMASK Cis-Demasking 1 cytokine technology in oral [...]
OSE Immunotherapeutics présente une nouvelle technologie bispécifique de « Cis-Démasquage » pour la conception de médicaments à base de cytokines avec un indice thérapeutique amélioré
17/10/2024
OSE Immunotherapeutics présente une nouvelle technologie bispécifique de « Cis-Démasquage » pour la conception de médicaments à base de cytokines avec un indice thérapeutique amélioré Nantes, France, le 17 octobre 2024 [...]
EssilorLuxottica: Q3/9M 2024 Revenue - Revenue keeping a solid 4% growth
17/10/2024
Q3/9M 2024 Revenue Revenue keeping a solid 4% growth Group’s revenue up 4.0% at constant exchange rates 1 in Q3, +4.9% year to date Revenue positive in both segments in all the regions in Q3 North America up low-single [...]

Pages